Transcript Paul Rodgers - Ithaka Life Sciences

Corporate presentation
January 2013
What we do
In depth technical expertise
Ithaka Track Record
• >190 assignments completed for >90 clients
• Worked with >25 universities on technology
commercialisation
• 9 university spin-outs created and financed
• >£30 million funding for clients
o Venture capital, corporate deals and grants
• Technical, commercial & IP evaluations undertaken for
>30 organisations
• Due diligence conducted for 9 investment funds
• Unrivalled network of contacts
Ithaka Team
• Paul Rodgers Founder & MD, experienced biotech
entrepreneur, biomarkers & personalised medicine
• John Adair Biopharmaceutical R&D (Axis Genetics,
Scotgen, Celltech, Searle)
• Richard Cumming Life science product development
& marketing (Amersham, GE Healthcare)
• Bill Primrose Drug discovery & development
(PanTherix, SioKem etc.)
• Mark Treherne Drug discovery & development
(Senexis, Cyclofluidic, BioFocus, Pfizer etc.)
• Paula Wittels Medical devices & diagnostics (Pfizer,
Quintiles etc.)
Ithaka: University Clients
Ithaka: Corporate Clients
creating a new cancer therapy
Typical Assignments
• Business creation & sourcing finance
 Psynova Neurotech & Smart Holograms
• Technical, commercial and market evaluation




Newcastle University: biofilm prevention
Manchester University: novel medical implant device
Scottish Enterprise: medical device, anaesthesia
University of Bath: human and animal vaccine technology
• Due diligence
 Apposite (Anaphore), Finance Wales (ADCB) & Wellcome (Kymab)
• Strategic advice
 ThermoFisher, Smith & Nephew, Wellcome Genome Campus
• Management, mentoring & coaching
 ProteinLogic, Scottish Enterprise & Theryte
• Portfolio review
 Bloomsbury Bioseed Fund
Case Study: Psynova Neurotech
• Biomarkers for psychiatric disorders
– Potential applications in diagnostics, drug discovery and
development
• Ithaka role
– Development of commercial strategy, business plan &
securing of finance in 2007
– Paul Rodgers: chairman from 2007 to 2012
• Results
–
–
–
–
–
University spin-out company 2007
> £8M investment & grant funding
First diagnostic product launched in 2010
Commercial deal with Roche Pharmaceuticals Dec 2009
Acquired by Myriad Genetics 2011
Why Work with Ithaka?
• Personal experience
–
–
–
–
–
Technology commercialisation
New ventures
Fund raising
Growth through strategic partnerships
Across the life science spectrum
• Multi-disciplinary team approach
• Unique network of contacts
• Support tailored to meet the client’s needs